Key Financial Data Of Reporting Company

Oncolys BioPharma Inc. - Filing #7339370

Concept As at
2024-03-31
2024-01-01 to
2024-03-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-03-31
2023-01-01 to
2023-03-31
Key financial data of reporting company
Business results of reporting company
Net sales
JPY
63,038,000 JPY
35,000,000 JPY
Ordinary profit (loss)
-363,292,000 JPY
-1,913,816,000 JPY
-323,092,000 JPY
Profit (loss)
-364,233,000 JPY
-1,938,505,000 JPY
-323,691,000 JPY
Equity in earnings (losses) of affiliates if equity method is applied
JPY
JPY
JPY
Share capital
3,945,814,000 JPY
3,623,165,000 JPY
3,000,000,000 JPY
Total number of issued shares
20,865,200 xbrli:shares
19,717,100 xbrli:shares
17,405,200 xbrli:shares
Net assets
1,748,158,000 JPY
1,474,097,000 JPY
1,835,577,000 JPY
Total assets
2,143,742,000 JPY
2,040,598,000 JPY
2,280,737,000 JPY
Dividend paid per share
Basic earnings (loss) per share
-18.24
-108.92
-18.69
Diluted earnings per share
Equity-to-asset ratio
0.812 xbrli:pure
0.715 xbrli:pure
0.801 xbrli:pure

Talk to a Data Expert

Have a question? We'll get back to you promptly.